ARVINAS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ARVINAS, INC. (ARVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.54 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $9.06, a 21.22% decline year-over-year.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $11.50, a 62.32% decline year-over-year.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $30.52, a 30.54% increase year-over-year.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $23.38, a 45.65% decline year-over-year.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $8.15, a 70.20% decline from fiscal 2024.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $27.35, a 24.37% increase from fiscal 2023.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $21.99, a 43.86% decline from fiscal 2022.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $39.17, a 25.88% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.54 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $9.06 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $8.15 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $12.46 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $12.54 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | $11.50 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $27.35 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $27.69 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $28.08 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $30.52 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $21.99 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $22.51 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $22.79 10-Q · filed 2024-07-30 | |||
| 2023-03-31 | $23.38 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $39.17 10-K · filed 2025-02-11 | |||
| 2022-09-30 | $39.69 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $41.41 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $43.02 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $52.85 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $27.45 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $13.28 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $9.88 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |